<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01055002</url>
  </required_header>
  <id_info>
    <org_study_id>QP09C08</org_study_id>
    <nct_id>NCT01055002</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Test Activity of Antimalarial Drugs Against an Induced Malaria Infection in Healthy Volunteers</brief_title>
  <official_title>A Pilot Phase II Study of the Efficacy of Antimalarial Drugs Against Plasmodium Falciparum by Experimental Challenge With a Low Dose of Blood Stage Parasites in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Queensland Institute of Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Q-Pharm Pty Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Trident Clinical Research Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicines for Malaria Venture</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study of a protocol for inducing a falciparum malaria infection in healthy
      volunteers in order to test the activity of novel agents being developed as drugs for the
      treatment of uncomplicated malaria. In this pilot study, 16 healthy male volunteers will be
      administered a low level malaria infection via infected human red blood cells. After 6 days
      they will be administered one of two registered antimalarial treatments (8 volunteers for
      each treatment) in order to define the rate of clearance of the infection. This information
      will be used to design similar future studies for the initial assessment of the efficacy of
      novel antimalarial drugs in development.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, controlled, randomized, study using a BSP inoculum challenge as a
      model to assess the activity of antimalarial agents. The study will be conducted in 2 cohorts
      (n = 6 and n = 10). Cohort 2 will not commence until at least after day 12 of cohort 1 and
      review by Safety Review Team following day 9 exit of cohort 1. The participants will be
      randomized 1:1 to the two registered antimalarials. This is an enabling study using
      registered antimalarial drugs as reference treatments (one slow acting and one fast acting),
      aimed to inform trial design, endpoints and testing regimens for assessing new candidate
      antimalarial drugs in development. The study will follow the sequence of the challenge
      inoculation, reference treatment and follow-up.

      Healthy male participants will be inoculated on Day 1 with ~1,800 Plasmodium
      falciparum-infected human erythrocytes administered intravenously. On an outpatient basis,
      participants will be monitored morning (AM) and night (PM) from day 3 to day 5 for adverse
      events and the unexpected early onset of symptoms, signs or parasitological evidence of
      malaria. On day 5 evening, participants will be admitted to the study unit and confined for
      safety monitoring and antimalarial treatment. Reference treatment administration will begin
      on the evening of Day 6 and continued on Day 7 and 8 (3 days of treatment).

      If clinical or parasitologic evidence of malaria (either the identification of two or more
      malaria parasites on a malaria thick film, platelet count less than 100 x109/L, or the onset
      of clinical features of malaria) occurs before day 6 evening, allocated treatment will begin
      at this time.

      Following treatment, participants will be followed up as inpatients for at least 86 hours, (4
      evenings) to ensure tolerance of the therapy and clinical response, then if clinically well
      on an outpatient basis for safety and continued presence of malaria parasites via PCR and
      thick blood film review.

      Adverse events will be monitored via telephone monitoring, within the clinical research unit
      and on outpatient review after malaria challenge inoculation and antimalarial study drug
      administration. Blood samples for safety evaluation, malaria monitoring, and red blood cell
      antibodies will be drawn at baseline and at nominated times after malaria challenge.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parasite clearance rates by PCR</measure>
    <time_frame>1-7 days after drug treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parasite growth rates by PCR</measure>
    <time_frame>1-6 days after inoculation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Healthy</condition>
  <condition>Non-smokers</condition>
  <arm_group>
    <arm_group_label>Artemether/lumefantrine tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Artemether (20 mg) and Lumefantrine (120 mg) tablets: Four tablets taken as a single dose twice a day with fatty food for three days (total dose of 24 tablets in 6 doses) on days 6-8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atovaquone/Proguanil HCl tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atovaquone (250 mg) and Proguanil HCl (100 mg) tablets: Four tablets taken as a single dose daily for 3 days (total dose of 12 tablets) on days 6-8</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood stage parasite (BSP) inoculum</intervention_name>
    <description>Inoculum of human red blood cells infected with falciparum malaria administered intravenously on Day 1</description>
    <arm_group_label>Artemether/lumefantrine tablets</arm_group_label>
    <arm_group_label>Atovaquone/Proguanil HCl tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males aged 18-45 years who do not live alone

          -  BMI within 18-30

          -  Understand the procedures and risks involved

          -  Contactable for the duration of the study

          -  Non-smokers and in good health

          -  Good venous access

        Exclusion Criteria:

          -  History of malaria

          -  Been in a malaria-endemic country within 12 months

          -  Evidence of cardiovascular risk

          -  Splenectomy

          -  History of severe allergic reactions after vaccination of infusion

          -  Any serious chronic illness

          -  Inherited genetic anomaly

          -  Any volunteers wishing to donate blood to the blood bank in the future

          -  Retinal or visual field changes

          -  Diagnosis of chronic severe psychiatric condition

          -  Hospitalisation within 5 years for psychiatric illness, suicide attempt or danger to
             self or others

          -  Receiving psychiatric drugs (some exceptions)

          -  Known QTc prolongation

          -  Family history of cardiac anomalies

          -  Recent or current therapy with an antibiotic or drug with potential antimalarial
             activity

          -  Known hypersensitivity to artemether or lumefantrine, atovaquone or proguanil
             hydrochloride or any of the excipients

          -  Concomitant use of any drug which is metabolised by the cytochrome enzyme CYP2D6 OR
             drugs that are known to prolong the QTc interval

          -  Use of corticosteroids, anti-inflammatory drugs, any immunomodulators or
             anticoagulants. Currently receiving or have previously received immunosuppressive
             therapy, including systemic steroids including ACTH or inhaled steroids in dosages
             which are associated with hypothalamicpituitary- adrenal axis suppression such as
             1mg/kg/day of prednisone or its equivalent or chronic use of inhaled high potency
             corticosteroids

          -  Presence of acute infectious disease or fever

          -  Evidence of acute illness within the four weeks before trial prior to screening

          -  Significant intercurrent disease of any type, in particular liver, renal, cardiac,
             pulmonary, neurologic, rheumatologic, or autoimmune disease by history, physical
             examination, and/or laboratory studies including urinalysis

          -  Alcohol consumption greater than community norms

          -  A history of drug habituation, or any prior intravenous usage of an illicit substance

          -  Medical requirement for intravenous immunoglobulin or blood transfusions

          -  Participation in any investigational product study within the 8 weeks preceding the
             study

          -  Participation in any research study involving significant blood sampling, or blood
             donation to a blood bank during the 8 weeks preceding the study

          -  Have ever received a blood transfusion

          -  Positive test for HIV, Hepatitis B, hepatitis C, Human T-cell Lymphotropic Virus I &amp;
             II (HTLVI &amp; HTLVII), and syphilis

          -  Any clinically significant biochemical or haematologic abnormality (Hb must be
             â‰¥13.5g/dL)

          -  Ingestion of any poppy seeds within the 48 hours prior to the screening blood test

          -  Detection of any recreational drug listed in the urine drug screen
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James McCarthy, MD FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queensland Institute of Medical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Q-Pharm Clinics, Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2010</study_first_submitted>
  <study_first_submitted_qc>January 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2010</study_first_posted>
  <last_update_submitted>June 23, 2011</last_update_submitted>
  <last_update_submitted_qc>June 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr James McCarthy</name_title>
    <organization>Queensland Institute of Medical Research</organization>
  </responsible_party>
  <keyword>Health male volunteers</keyword>
  <keyword>Male volunteers aged 18-45 years</keyword>
  <keyword>Non-smokers and in good health</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Antimalarials</mesh_term>
    <mesh_term>Atovaquone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

